PubMed Health⌕ Search

Biomedical subjects

J Masopust

Publications and source records attributed to J Masopust.

At least 37 records · Page 2Linked to original sources
PubMed1981

[Therapeutic results in lymphogranulomatosis and their relationship to immunological reactivity].

The efficacy of two treatment modalities of Hodgkin's disease stages I-IV (1) local irradiation of COPP chemotherapy with protracted low-dosage cyclophosphamide administration, or (2) all-round irradiation of lymphatic vessels or the same COPP treatment combined with shock doses of cyclophosphamide is evaluated. Duration of the first remission and survival time were followed in 45 patients in 1969-1978. During remission, some patients received a non-specific immunotherapy (BCG vaccination). The cumulative index of the first remission appeared to increase from 19 to 72% (radiation therapy) and from 14 to 68% (chemotherapy) within 3 years in the case of the second modality. The survival time of patients did not differ significantly in both study groups. Remission was longer in patients who had received BCG vaccination.

Antigen-Antibody Reactions↗
PubMed1981

Retrospective study in 430 patients with Hodgkin's disease (1965-1974).

The authors from 11 institutions in the Czech Socialist Republic, grouped into a Complex Rationalisation Brigade for the diagnosis and therapy of the malignant lymphogranuloma, present results of a retrospective study in 430 patients with Hodgkin's disease. The results were obtained after the data treatment on a digital computer and concern with a general characteristic of the group of patients, that involved 57,2% men and 42,8% women with a peak of the age distribution between 20 and 30 years and a second peak between 60 and 70 years. In the clinical data there is an analysis of the rate of occurring the lesion in particular groups of nodes, where the nodes of mediastinum and of the neck were involved most frequently. In the therapeutic procedures the radiotherapy, cytostatic therapy and their combination are evaluated. The 5-year survival in the whole group is of 41%. Out of this, in the first five years of the period of interest and in the second five years, the numbers of the surviving patients were of 33 and 47% respectively. In the Tables, there are complete remissions, mean times of the remission and longest time of the remission for different methods of the therapy. When evaluating the relapse of the disease, it was possible to observe not only the dependence on the total time of irradiation but also on the time distribution of the dose. The patients with involved nodes above the diaphragm have a better prognosis than those with lesions of nodes in the subdiaphragm region.

Adolescent↗
PubMed1980

Individual changes of DNA catabolite excretion in the course of antitumor therapy of Hodgkin's disease.

In patients with morbus Hodgkin, treated primarily by the actino- and chemotherapy, the excretion was followed of DNA catabolites (deoxycytidine, deoxyuridine, thymidine and their sum) in the course of the therapy. The dynamics was studied of changes in the time interval of interest and attention was paid to its relation to the clinical and histological type of disease and to the successful character of the therapy defined by reaching a complete remission. The group of patients as a whole was characterized by an increased excretion of catabolites in the time interval of interest. No dependence was demonstrated between the catabolite excretion and extent of the disease similarly as between the excretion and successful character of the therapy. The dynamics of the changes in the time intervals of interest was neither remarkably nor continuously increased or decreased. The test of the excretion of pyrimidine deoxyribonucleosides possesses sufficient sensitivity for demonstrating laws in relation to the therapy during group evaluation. With respect to individual variability of values of particular patients and to the absence of the relations mentioned above the test is not suitable to indicate the individual response to the anticancer therapy.

Cyclophosphamide↗